Latest Breaking News On - Derrell porter - Page 1 : comparemela.com

Passage Bio : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K -December 29, 2023 at 04:19 pm EST

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE TARA M. WILLIAMS, derivatively on behalf of PASSAGE BIO, INC., .

State of delawareUnited statesNew castle countyGinam serraDerrell porterMaxime gowenSethd rigrodskyAthena countouriotisSaqib islamTaram williamsSandip kapadiaHerbert mondrosSusanw waescoThomas woiwodeCompensation committeeOffice of the register in chancery

cTRL Therapeutics Appoints Ruben Rodriguez, Ph D , as Head of Research

cTRL Therapeutics Appoints Ruben Rodriguez, Ph D , as Head of Research
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaDerrell porterRuben rodriguezSalk institute for biologicalGlobal head of research at instilbioHead of researchAppoints ruben rodriguezGlobal headKite pharmaMolecular biologyHospital clinicSalk instituteBiological studies

Longtime BioMarin CEO hands off baton—Chutes & Ladders

Longtime BioMarin CEO hands off baton—Chutes & Ladders
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Ocuphire pharmaAmit mehtaDerrell porterKirsty sempleErin lavelleCellevolve bioSarah coleTodd dickinsonAdrian rayPaul frohnaMichelle shuffettJennifer towneMarguerite hutchinsonChristian howellLori kunkelDaiichi sankyo plexxikon

cTRL Therapeutics Appoints Derrell D Porter, M D , as Chief Executive Officer

/PRNewswire/ cTRL Therapeutics, a biotechnology company harnessing circulating tumor-reactive lymphocytes (cTRLs) in the blood to broaden the power and.

Shana kelleyDerrell porterLos angelesCellevolve bioDerrelld porterHealth care managementWharton schoolUniversity of pennsylvania perelman school medicineGilead sciencesMckinsey companyChief executiveChief executive officerChief technology officerPassage bioAcumen pharmaAtara bio

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, completed enrollment in February 2023 Topline data expected in the third quarter of 2023 Cash, cash. | March 27, 2023

United statesDaniel oconnellDerek meisnerAlex braunDerrell porterLiean schenckAtara biotherapeutics incAcumen pharmaceuticals incClinical developmentCompany phaseExchange commissionDevelopment rd expensesDrug administrationDanielo connellChief executive officerBusiness highlights